I completely agree - their IP assosiated with kevetrin alone covers well beyond kevetrin.  Everyone doing DD be sure to look at the advisory boards and the patent expertise of Dr. Paul Ginsberg (link below).  A protected pipeline like this... finally with the active studies (multiple active studies for multiple compounds soon) the publicity will finally invite the market to give CTIX their true valuation - I am really looking forward to that!

http://cellceutix.com/team/